Hitachi Solutions India inaugurated the company’s second global development center in Hyderabad, in the southern state of Telangana, and will hire over 400 engineers at its Chennai and Hyderabad facilities over the next 18 months. Ananth Subramanian, CEO and managing director, Hitachi Solutions, said the company had signed an agreement...
Global India Business Meeting, No-Charge, Los Angeles November 14
On Saturday, November 14 2015, from noon to 5 PM at the storied Westin Bonaventure Hotel in downtown Los Angeles, the Indian government has organized a free Indian Diaspora Business Meet. Advance registration is required at http://www.oifc.in/registration-oifc-business-meet-november-14-2015 Arrive at 11 am to network, enjoy the provided lunch at noon and...
Ikea to Operate 25 Stores in India
The Swedish home furnishings company IKEA has announced a long term plan to open 25 stores in the country at a cost of $80 million per store. In July this year the company bought land in Hyderabad in south India for its maiden store. Business Standard reports that IKEA has...
Dr. Reddy’s Laboratories Shuffles Top Management
With the North America head Umang Vora parting ways with the Hyderabad-based drug maker, Alok Sonig has been appointed to replace him. Sonig had worked for Bristol-Meyers to drive its commercial excellence and business model innovation functions at Princeton, New Jersey, before moving to Dr. Reddy’s. Currently he is responsible...
Aurobindo Pharma, India, Scales Up to Meet U.S. Requirements
According to LiveMint, Hyderabad-based Aurobindo Pharma is planning to scale up its capacity as it expects more launches in its key U.S. market. It also plans to make India its sourcing hub for its generic drug business in Western Europe – a business that it had acquired from Actavis Plc....
India’s Dr. Reddy’s Lab Strategizes for the U.S. Market
Financial Express reports that India's Dr. Reddy's Laboratories, based in the southern city of Hyderabad, disclosed plans to expand in the U.S. and emerging markets this year; widen its reach in Europe; invest in new drugs that offer higher margins such as complex generics, biosimilars and proprietary products; and promote...